Further optimization of a CDK5/p35 kinase inhibitor that is both potent and selective would thus treat cancer through both NK-dependent and NK-independent mechanisms, potentially improving outcomes compared with using just either strategy alone. The gene discussed is CDK5; the disease is cancer.